ProteinQure’s Post

Plus Therapeutics presented data on its novel radioisotope rhenium-186 at the annual meeting of the Society of Nuclear Medicine & Molecular Imaging (SNMMI) in Toronto. Link to presentation: https://bit.ly/4bd9GyB An oral presentation titled, “Radiation Absorbed Dose to Spinal Cord: Therapy of Leptomeningeal Metastases Using Beta-Emission Pharmaceuticals”, brief highlights: - Data from the ReSPECT-LM clinical trial was used to evaluate the safety and potential spinal cord toxicity of beta-emission radioisotopes, including 177Lu, 131I, 186Re, 188Re, and 90Y - Higher beta-energy emitters (i.e., 188Re and 90Y) give higher radiation absorbed doses to spinal cord with more heterogeneous radiation absorbed doses to spinal fluid - Lower beta-energy radionuclides (177Lu, 131I, and 186Re) can largely spare the spinal cord, presenting a promising approach to minimize toxicity while delivering high doses to eradicate cancer cells #nuclearmedicine #clinicaltrials #radiotherapy

Now you can read the full paper and watch the interview about the OTCsurvey4residents

Bromo Biliaron is a radiopharmaceutical used in hepatobiliary imaging, and it contains bromotrimethylaminomethyliminodiacetic acid (mebrofenin) labeled with the radioisotope technetium-99m (Tc-99m). Tc-99m Mebrofenin (technetium-99m mebrofenin) is a radiopharmaceutical used in nuclear medicine, primarily for hepatobiliary imaging. It helps in evaluating liver function, gallbladder function, and the patency of the bile ducts. Technetium-99m (Tc-99m) is a widely used radioisotope in diagnostic imaging because of its ideal physical characteristics, including a half-life of approximately 6 hours and the emission of gamma rays suitable for detection with a gamma camera. 🖇️ Mechanism of Action After intravenous injection, mebrofenin is taken up by hepatocytes and excreted into the bile. The Tc-99m emits gamma rays, which can be detected by a gamma camera to produce images of the hepatobiliary system. Photo by: Dame Ria Silaban #nuclearmedicine

🇳🇱⚛️🤝 NRGIPALLAS (ENS Corporate Member) and Curium Pharma have signed a long-term agreement to expand the current #cooperation to include the production of #lutetium-177 (Lu-177). This agreement will enable Curium to supply about 70,000 doses of Lu-177 annually, which will help about 14,000 patients per year. 🏥⚛️❤️ Lu-177 is currently used in hospitals to treat neuroendocrine tumours, and it is also a very promising #radioisotope used in the fight against prostate cancer and dozens of other applications soon. That's why the need for Lu-177 is expected to grow exponentially: from 16,000 patients in 2020 to 138,000 patients in 2026. 🔬⚛️🚚 NRGIPALLAS’ HFR reactor and Curium’s Lu-177 production facility are both located at the Energy & Health Campus in #Petten, which also means that no time is lost in the production of lutetium (half-life) and the #nuclear #medicine can reach #patients as quickly as possible. ✅ https://lnkd.in/dQNJ_V69

Good morning #baltimore! Rene Rebeaud, David Eckels and Andrew Prideaux are all ready to welcome you in booth #5 at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Therapeutics Conference. Come by today or tomorrow and discuss with them what opportunities and challenges you are facing with your #theranostics programs. You will discover how the #allinone #hermia #software can help you easily and efficiently deliver personalized treatments for your patients. See you there! #theranostics #personalized #dosimetry #radiopharmaceuticals #therapeutics #software #innovation #hermia #nuclearmedicine #molecularimaging

The data, published in the International Journal of Molecular Sciences, demonstrate that opaganib significantly improved long-term survival in an in vivo model of lung damage following exposure to ionizing radiation Opaganib is the first selective sphingosine kinase-2 (SPHK2) inhibitor investigational drug targeting sphingolipid metabolism for the treatment of radiation-induced inflammation Opaganib, a novel oral, small molecule pill with a five-year shelf-life, is easy to administer and distribute, supporting potential central government stockpiling for use as radioprotection therapy in mass casualty radiological or nuclear incidents, if approved by the FDA https://lnkd.in/gUrmXe9A

𝐃𝐞𝐭𝐞𝐜𝐭𝐢𝐧𝐠 𝐏𝐫𝐨𝐬𝐭𝐚𝐭𝐞 𝐂𝐚𝐧𝐜𝐞𝐫: 5 𝐖𝐚𝐫𝐧𝐢𝐧𝐠 𝐒𝐢𝐠𝐧𝐬 𝐭𝐨 𝐖𝐚𝐭𝐜𝐡 𝐎𝐮𝐭 𝐅𝐨𝐫   Prostate cancer is a significant health concern, affecting one in eight men during their lifetime. Early detection is crucial for successful management and treatment of prostate cancer. Here are the five main symptoms of prostate cancer:   ·      Blood in your urine or semen ·      Frequent urination ·      Painful urination or difficulty urinating ·      Sudden erectile dysfunction ·      Bone pain With a legacy going back more than 60 years, Curium’s teams are focused on developing innovative solutions to combat prostate cancer. We are driven by the desire to improve patients' quality of life and to ultimately redefine the experience of cancer through our trusted legacy in nuclear medicine. https://lnkd.in/dSpf-ENs     #ProstateCancerAwareness #MensHealthMatters #EarlyDetectionSavesLives #ProstateCancer #PSMA #NuclearMedicine #PrecisionMedicine #ClinicalTrial

RENAL CELL CARCINOMA can be hard to see with 18F-FDG and more if the reader Is improvised or inexperienced. In clinical practice we are expecting have new radiotracers like the one that Telix Pharmaceuticals Limited is in ways of development. | The MedicinaNuclearMX collective are Mexican Nuclear Medicine Physicians promoting, expanding clinical use & doing disruptive business by private sector in Mexico. #molecularimaging #nuclearmedicine #theranostics #radionuclidetherapy #renalcancer

🌟 Introducing IsoMedica (an entX Limited company)! 🌟 We’re excited to unveil our new brand dedicated to Nuclear Medicine supply chains, IsoMedica. At IsoMedica, we're pioneering Mine to Medicine technologies to recover valuable isotopes from low-level radioactive waste streams as well as providing valuable precursors to the nuclear medicine supply chain. These isotopes will feed critical and emerging cancer therapy treatments. Our mission extends beyond innovation – we're reshaping the landscape of cancer therapy by breaking reliance on existing supply chains. With geopolitical issues causing instability in some countries, creating a sovereign supply chain is essential. By doing so, we're enhancing the availability and reducing the cost of future cancer treatments, not just in Australia, but across the globe. Join us in this groundbreaking journey towards a brighter, more accessible future for cancer care. Read more: 👉 https://lnkd.in/gKc2J6tF #IsoMedica #CancerTherapy #Innovation #entX #Radiopharmaceuticals #NuclearMedicine #IsotopeRecovery #MedTech #GlobalHealthcare #CancerResearch #SupplyChainSecurity #AccessibleTreatment #FutureOfMedicine #Australia #minestomedicines Massey de los Reyes | Julian F. Kelly | Bryn Jones

“Elizabeth, what is the company you work for again? And what do you do?” I hear this A LOT from my friends and family. ☺️ (The next post is about what I do, stay tuned!) So, here goes - I work for Curium Pharma, a global company dedicated to redefining the experience cancer through our trusted legacy in nuclear medicine. More about Curium Pharma can be found in the link below.